Polypid Ltd (PYPD)

$5.02 -0.03 (-0.59%)
Market Cap 95.80M
Revenue (ttm) 0.00
Net Income (ttm) -34.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 223,800
Avg Vol 131,568
Day's Range N/A - N/A
Shares Out 19.08M
Stochastic %K 69%
Beta 1.40
Analysts Strong Sell
Price Target $12.25

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
Finnish_boy
Finnish_boy Jul. 4 at 3:34 PM
$PYPD Doesnt mean anything but in 2022 they announced EU partnership deal at start of August on Wednesday a week before Q2 report also.
0 · Reply
Finnish_boy
Finnish_boy Jul. 4 at 3:25 PM
$PYPD My best guess. But you never know.
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:55 PM
$SLS $ATHE $CING $PYPD It's been 1 year (and 2 days) since I posted this. How did you guys do this year? What do you guys have planned for the next year? Are you paying attention (and contributing) to the Discord?
2 · Reply
PaulNipkow
PaulNipkow Jul. 3 at 8:55 AM
$PYPD Nap time over soon ?
1 · Reply
PaulNipkow
PaulNipkow Jul. 2 at 8:25 AM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Jul. 2 at 6:47 AM
$PYPD Would be super helpful to know when the deal will be out. Is it late August after NDA approval or is it mid-July. I dont know.
0 · Reply
Finnish_boy
Finnish_boy Jun. 30 at 8:14 AM
$PYPD Management has very high ambitions. They go alone but the first programs will be partnered being more cost-friendly. They are already planning where they build a second factory.
1 · Reply
Finnish_boy
Finnish_boy Jun. 30 at 7:47 AM
$PYPD Future giant pharma? Scalable platform technology with super robust PH3 data. Market cap under 100M. "As a delivery platform, it can be applied to multiple classes of therapeutics that struggle with stability, toxicity, or dosing frequency under traditional systemic administration." https://pulse2.com/polypid-profile-ori-warshavsky-interview/
0 · Reply
Finnish_boy
Finnish_boy Jun. 29 at 9:20 PM
$PYPD Look at volume. Big green days high volume. Big boys try to load as much as they can under $5. Pretty transparent.😂if retail investors were active on this stock, stock would be already $10
1 · Reply
Finnish_boy
Finnish_boy Jun. 29 at 4:00 PM
$PYPD TICK TOCK. Bigger players dont want to SP shoot up !! warrants sellers are their friends, they can short sell some to control SP, shorties were up 200%. It's all about couple of weeks waiting anymore. I have totally full position. SP going to $10 by August. Next year $20.
0 · Reply
Latest News on PYPD
PolyPid completes NDA submission to FDA for D-PLEX100

2026-06-01T14:27:56.000Z - 4 weeks ago

PolyPid completes NDA submission to FDA for D-PLEX100

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Jun 1, 2026, 8:30 AM EDT - 4 weeks ago

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

May 28, 2026, 11:30 AM EDT - 5 weeks ago

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

May 20, 2026, 8:30 AM EDT - 6 weeks ago

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid reports Q1 EPS (35c), consensus (43c)

2026-05-13T17:09:41.000Z - 7 weeks ago

PolyPid reports Q1 EPS (35c), consensus (43c)

PolyPid Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

PolyPid Earnings Call Transcript: Q1 2026

PolyPid Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

PolyPid Earnings release: Q1 2026

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 13, 2026, 7:30 AM EDT - 7 weeks ago

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Apr 28, 2026, 8:30 AM EDT - 2 months ago

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Apr 13, 2026, 9:15 AM EDT - 2 months ago

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

Mar 31, 2026, 8:30 AM EDT - 3 months ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid granted $4.3M waiver from FDA for D-Plex application

2026-03-17T12:46:11.000Z - 3 months ago

PolyPid granted $4.3M waiver from FDA for D-Plex application

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 17, 2026, 8:30 AM EDT - 3 months ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:40 PM EDT - 4 months ago

PolyPid Transcript: The Citizens Life Sciences Conference 2026

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 25, 2026, 8:35 AM EST - 4 months ago

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:30 AM EST - 5 months ago

PolyPid Earnings Call Transcript: Q4 2025

PolyPid Annual report: Q4 2025

Feb 11, 2026, 8:30 AM EST - 5 months ago

PolyPid Annual report: Q4 2025

PolyPid Earnings release: Q4 2025

Feb 11, 2026, 8:30 AM EST - 5 months ago

PolyPid Earnings release: Q4 2025

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 7:30 AM EST - 5 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Slides: Investor presentation

Feb 11, 2026, 6:00 AM EST - 5 months ago

PolyPid Slides: Investor presentation

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 28, 2026, 8:00 AM EST - 5 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 10:30 AM EST - 6 months ago

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

PolyPid appoints Story as Chairman of Board of Directors

2025-12-16T13:41:48.000Z - 7 months ago

PolyPid appoints Story as Chairman of Board of Directors

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 16, 2025, 8:30 AM EST - 7 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid Transcript: KOL Event

Dec 10, 2025, 11:30 AM EST - 7 months ago

PolyPid Transcript: KOL Event

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

2025-12-03T13:35:51.000Z - 7 months ago

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Dec 3, 2025, 8:30 AM EST - 7 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 25, 2025, 8:30 AM EST - 7 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

PolyPid Slides: Corporate Presentation

Nov 18, 2025, 7:00 AM EST - 8 months ago

PolyPid Slides: Corporate Presentation

PolyPid price target lowered to $9 from $10 at Roth Capital

2025-11-13T11:16:03.000Z - 8 months ago

PolyPid price target lowered to $9 from $10 at Roth Capital

PolyPid Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

PolyPid Earnings Call Transcript: Q3 2025

PolyPid Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

PolyPid Earnings release: Q3 2025

PolyPid sees cash runway ‘well into’ 2026

2025-11-12T12:41:32.000Z - 8 months ago

PolyPid sees cash runway ‘well into’ 2026

PolyPid reports Q3 EPS (37c), consensus (52c)

2025-11-12T12:35:15.000Z - 8 months ago

PolyPid reports Q3 EPS (37c), consensus (52c)

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:30 AM EST - 8 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Nov 6, 2025, 8:30 AM EST - 8 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Oct 29, 2025, 8:30 AM EDT - 8 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 12:30 PM EDT - 9 months ago

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 9 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 10 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid completes Israeli Ministry of Health GMP inspection

2025-09-16T12:45:43.000Z - 10 months ago

PolyPid completes Israeli Ministry of Health GMP inspection

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 10 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 10 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 10 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid price target lowered to $13 from $15 at Craig-Hallum

2025-08-14T13:30:37.000Z - 11 months ago

PolyPid price target lowered to $13 from $15 at Craig-Hallum

PolyPid price target raised to $10 from $9 at Roth Capital

2025-08-14T12:05:26.000Z - 11 months ago

PolyPid price target raised to $10 from $9 at Roth Capital

PolyPid Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 11 months ago

PolyPid Earnings Call Transcript: Q2 2025

PolyPid Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 11 months ago

PolyPid Earnings release: Q2 2025

PolyPid reports Q2 EPS (78c), consensus (55c)

2025-08-13T11:35:50.000Z - 11 months ago

PolyPid reports Q2 EPS (78c), consensus (55c)

PolyPid sees cash runway ‘well into’ 2026

2025-08-13T11:35:37.000Z - 11 months ago

PolyPid sees cash runway ‘well into’ 2026

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 11 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid appoints Tweezer-Zaks as Chief Medical Officer

2025-08-12T12:20:23.000Z - 11 months ago

PolyPid appoints Tweezer-Zaks as Chief Medical Officer

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 11 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid files to sell 7.63M ordinary shares for holders

2025-07-29T20:12:22.000Z - 1 year ago

PolyPid files to sell 7.63M ordinary shares for holders

PolyPid Registration statement: Registration Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

PolyPid Registration statement: Registration Filing

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 1 year ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid price target lowered to $9 from $12 at Roth Capital

2025-06-18T12:06:16.000Z - 1 year ago

PolyPid price target lowered to $9 from $12 at Roth Capital

PolyPid price target lowered to $9 from $12 at Roth Capital

2025-06-17T15:05:27.000Z - 1 year ago

PolyPid price target lowered to $9 from $12 at Roth Capital

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 1 year ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid Slides: Corporate Presentation

Jun 12, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Corporate Presentation

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 1 year ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 1 year ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 1 year ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Transcript: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Transcript: Status Update

PolyPid Press release: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Press release: Status Update

PolyPid Slides: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Slides: Status Update

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 1 year ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid Slides: Investor Presentation

Jun 9, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Investor Presentation

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 1 year ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 1 year ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

May 29, 2025, 10:15 AM EDT - 1 year ago

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q1 2025

PolyPid Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings release: Q1 2025

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 11:20 AM EST - 1 year ago

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

PolyPid Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q4 2024

PolyPid Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Annual report: Q4 2024

PolyPid Earnings release: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings release: Q4 2024

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PolyPid Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

PolyPid Registration statement: Registration Filing

PolyPid Slides: Corporate Presentation

Jan 14, 2025, 6:00 PM EST - 1 year ago

PolyPid Slides: Corporate Presentation

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PolyPid Transcript: 2024 Sidoti Virtual Micro-Cap Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

PolyPid Transcript: 2024 Sidoti Virtual Micro-Cap Conference

PolyPid Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q3 2024

PolyPid Earnings release: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

PolyPid Earnings release: Q3 2024

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Finnish_boy
Finnish_boy Jul. 4 at 3:34 PM
$PYPD Doesnt mean anything but in 2022 they announced EU partnership deal at start of August on Wednesday a week before Q2 report also.
0 · Reply
Finnish_boy
Finnish_boy Jul. 4 at 3:25 PM
$PYPD My best guess. But you never know.
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:55 PM
$SLS $ATHE $CING $PYPD It's been 1 year (and 2 days) since I posted this. How did you guys do this year? What do you guys have planned for the next year? Are you paying attention (and contributing) to the Discord?
2 · Reply
PaulNipkow
PaulNipkow Jul. 3 at 8:55 AM
$PYPD Nap time over soon ?
1 · Reply
PaulNipkow
PaulNipkow Jul. 2 at 8:25 AM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Jul. 2 at 6:47 AM
$PYPD Would be super helpful to know when the deal will be out. Is it late August after NDA approval or is it mid-July. I dont know.
0 · Reply
Finnish_boy
Finnish_boy Jun. 30 at 8:14 AM
$PYPD Management has very high ambitions. They go alone but the first programs will be partnered being more cost-friendly. They are already planning where they build a second factory.
1 · Reply
Finnish_boy
Finnish_boy Jun. 30 at 7:47 AM
$PYPD Future giant pharma? Scalable platform technology with super robust PH3 data. Market cap under 100M. "As a delivery platform, it can be applied to multiple classes of therapeutics that struggle with stability, toxicity, or dosing frequency under traditional systemic administration." https://pulse2.com/polypid-profile-ori-warshavsky-interview/
0 · Reply
Finnish_boy
Finnish_boy Jun. 29 at 9:20 PM
$PYPD Look at volume. Big green days high volume. Big boys try to load as much as they can under $5. Pretty transparent.😂if retail investors were active on this stock, stock would be already $10
1 · Reply
Finnish_boy
Finnish_boy Jun. 29 at 4:00 PM
$PYPD TICK TOCK. Bigger players dont want to SP shoot up !! warrants sellers are their friends, they can short sell some to control SP, shorties were up 200%. It's all about couple of weeks waiting anymore. I have totally full position. SP going to $10 by August. Next year $20.
0 · Reply
PaulNipkow
PaulNipkow Jun. 29 at 10:42 AM
$PYPD the best example that ppl are like sheep (… no, not the smart ones from the movie *Sheep Detectives*) ! They all follow one another, and for the most part, they’re blind to what’s right in front of them and deaf to what’s being said. 780m by Lilly vs 1/10 here for a phase 3
0 · Reply
Finnish_boy
Finnish_boy Jun. 28 at 6:45 PM
$PYPD CEO refers Camurus x Eli Lilly deal.. up to 870M !! PolyPid market cap under 100M !! Potential multibagger already within a year. I think they sign partnerhship also with GPL-1 program already next year !!🤑
2 · Reply
Finnish_boy
Finnish_boy Jun. 28 at 11:00 AM
$HROW $PYPD Buy both as much as you can under $50 and $5 levels. Both will more than double within a year.
0 · Reply
Finnish_boy
Finnish_boy Jun. 28 at 7:38 AM
$PYPD SSI: D-PLEX100 FDA approval Q1 2027 GLP-1: PP03A preclinical package this year Oncology: OncoPlex (docetaxel) proof of concept, PP04A controlled and prolonged intratumoral delivery of a STING agonist, developed in collaboration with Immunogenesis.
0 · Reply
Finnish_boy
Finnish_boy Jun. 27 at 1:57 PM
$PYPD 🚨CEO "super excited about this program": Ultra-long GLP-1 Receptor Agonist designed for +50 days of linear release, maintaining effective blood concentrations without the peaks and troughs of currently available treatments. Opportunity is massive🔥Things can go crazy🤑
0 · Reply
Finnish_boy
Finnish_boy Jun. 27 at 9:53 AM
$PYPD GLP-1 program another big partnership, maybe they will sign already next year! They will expand that program also to other use of cases. Lilly deal 870M vs PYPD MC 90M !!!! markets wake up!
0 · Reply
Finnish_boy
Finnish_boy Jun. 27 at 9:51 AM
$PYPD This time no different: a lucrative US partnership deal around the corner. Brooke Story, Veteran MedTech Leader, knows very well all the potential partners. Multiple interested parties have been in the negotiations. https://thefinanceherald.com/an-industry-respected-biotech-award-just-recognized-polypid-an-under-the-radar-microcap-with-major-data/
0 · Reply
Finnish_boy
Finnish_boy Jun. 27 at 5:17 AM
$PYPD Never seen better setup. I have very big position. Once in lifetime opportunity. Under $5 is biggest robbery ever! $10 is next stop..very soon!
0 · Reply
Finnish_boy
Finnish_boy Jun. 27 at 5:14 AM
$PYPD When markets will wake up!!!! Lilly pays $700M for ph1 vaccine.. same problem SSI.. tons of uncertainty.. earliest on the market 2033, probably not until 2035, and quite likely it will fail.. PolyPid product works.. prevents more widely pathogens. On the market 2027. Wake up guys!! 720M vs 90M !!!! PolyPid = multibagger !!
2 · Reply
WallStWireAds
WallStWireAds Jun. 26 at 6:30 PM
$PYPD Lilly's $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid's Asset is Hiding in Plain Sight >> https://www.benzinga.com/content/60113986/lilly-s-780m-bet-reshaping-surgical-infection-prevention-and-polypid-s-asset-hiding-plain-sight $LLY $CING $MDT $NVCT
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jun. 26 at 3:42 PM
$PYPD @Disco_Vader And I watching my baby linger... No partnership announcement... Stock trading flat for months... While all my other picks go to the: thats-no-moon...
1 · Reply
Finnish_boy
Finnish_boy Jun. 26 at 2:35 PM
$PYPD
0 · Reply